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Objective
To identify problems and difficulties in determining a
non-inferiority (NI) margin using the case of NI rando-
mized controlled trials (RCTs) of oral anti-thrombolytic
agents for prophylaxis of venous thromboembolic events
(VTE) after orthopedic surgery.
Methods
We searched in Pubmed and Cochrane-central-register-
for-controlled-trials for all NI RCTs of direct thrombin
inhibitors (DTI) and direct inhibitors of factor Xa
(DXAI) for prophylaxis of VTE. All NI trials had enoxa-
parin as their active comparator. Using the draft FDA
guidelines for NI trials, we determined an NI margin,
referred to as the reference NI margin, based on all pub-
lished placebo-controlled trials on enoxaparin for the
same indication, identified in PubMed and Cochrane-
central-register-for-controlled-trials. We used preserved-
effects of 50% and 67% to calculate the reference NI
margin.
Results
We identified 12 NI trials and 4 placebo-controlled
trials of enoxaparin from our searches. All NI trials
studied oral drugs. Trials in DTI used the risk differ-
ence (RD) to define their NI margin, and it ranged
from 0.02 to 0.092. Trials in DXAI used the RD
(ranging from 0.035 to 0.056) or risk ratio (RR) (1.25)
or both to define their NI margin. Furthermore, the NI
margins using the RD were stricter than the 50% pre-
served-effects reference NI margin ((0.02 to 0.092) vs.
0.115). The NI margins in the trials using the RR were
stricter than the 50 and 67% preserved-effects refer-
ence NI margin (1.25 vs. 1.46 and 1.28). In one trial,
the test drug might have been concluded as non-infer-
ior to enoxaparin if the 50% preserved-effects reference
NI margin of RR were used.
Conclusions
Although a same comparator was used, a large variation
in NI margins among NI RCTs of oral anti-thrombolytic
agents for prophylaxis of VTE after orthopedic surgery
exists. Using different NI margins could lead to different
conclusions of the drug’s efficacy. Challenges that
became apparent during determination of an NI margin
were 1) missing unpublished results of placebo-con-
trolled trials, 2) how similar should placebo-controlled
trials and NI trials be to maintain the constancy
assumption, 3) whether fixed or random effects analysis
should be used in the meta-analysis, 4) whether to cal-
culate the NI margin on an absolute or relative scale, 5)
which preserved-effects to use, and 6) whether further
clinical judgment is needed.
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